Thrasos

Nephraegis Therapeutics

Nephraegis Therapeutics develops small molecule drugs to prevent and treat acute kidney injury for patients undergoing cardiovascular and abdominal surgical procedures.

Trestle Biotherapeutics

This company develops implantable bioengineered kidney tissues to restore renal function for patients suffering from end-stage renal disease.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

Nephris

The company develops therapies for chronic kidney disease in diabetic patients.

Pathalys Pharma

This biopharmaceutical company develops treatments for secondary hyperparathyroidism in patients with end-stage kidney disease undergoing dialysis.

Purespring Therapeutics

This company develops gene therapies for patients with chronic renal diseases to preserve kidney function and treat conditions like IgA nephropathy.

Estuary Biotherapeutics

This biotechnology company develops targeted genetic medicines for patients with serious kidney conditions, specifically autosomal dominant polycystic kidney disease.

Kynos Therapeutics

This biopharmaceutical company develops kynurenine 3-monooxygenase inhibitors to treat patients with acute and chronic inflammatory diseases including acute pancreatitis and kidney injury.